APA (7th ed.) Citation

C, M., N, A., S, B., RJ, B., JB, C., ME, C., . . . SS, L. (2021). Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle & nerve, 64(3), 309. https://doi.org/10.1002/mus.27339

Chicago Style (17th ed.) Citation

C, Milligan, et al. "Tocilizumab Is Safe and Tolerable and Reduces C-reactive Protein Concentrations in the Plasma and Cerebrospinal Fluid of ALS Patients." Muscle & Nerve 64, no. 3 (2021): 309. https://doi.org/10.1002/mus.27339.

MLA (9th ed.) Citation

C, Milligan, et al. "Tocilizumab Is Safe and Tolerable and Reduces C-reactive Protein Concentrations in the Plasma and Cerebrospinal Fluid of ALS Patients." Muscle & Nerve, vol. 64, no. 3, 2021, p. 309, https://doi.org/10.1002/mus.27339.